FDA Issues Voluntary Recall of Duloxetine Due to Carcinogenic Impurities

The FDA has issued a voluntary recall of the antidepressant duloxetine due to carcinogenic impurities, specifically N-nitroso-duloxetine. Rising Pharmaceuticals initiated the recall affecting over 233,000 bottles, highlighting ongoing concerns about nitrosamine contamination in medications. Patients are advised to consult healthcare providers for guidance and alternative treatment options. Stay informed about medication safety and recalls to protect your health.